Rana R. McKay, MD, presented “Trials in Neoadjuvant Therapy for Patients with High-Risk Localized Prostate Cancer” for the Grand Rounds in Urology audience in October 2020.
Presentation Summary:
Rana R. McKay, MD, Associate Professor of Medicine at the University of California, San Diego, and Co-Leader of the Genitourinary Oncology Disease Team at the Moores Cancer Center, discusses neoadjuvant hormonal therapy for patients with high-risk localized prostate cancer. Neoadjuvant therapy has been shown to be beneficial to patients with breast, rectal, bladder, and other cancers, but historic neoadjuvant trials in prostate cancer have had limited long-term follow-up and have failed to systematically evaluate pathologic response. More recent trials are seeking to remedy these gaps, and results from a recent phase 2 trial indicate that a subset of high-risk patients do benefit greatly from intense neoadjuvant hormonal therapy. Dr. McKay explains that the phase 3 PROTEUS trial, which is currently recruiting, will hopefully allow researchers to better define exceptional responders and non-responders, identify intermediate pathologic endpoints, and figure out how best to integrate imaging and tissue biomarkers to guide neoadjuvant therapy selection for prostate cancer patients.
Q&A Summary:
E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology and Professor of Urology at the University of California, San Diego, discusses neoadjuvant therapy for high-risk localized prostate cancer with Rana R. McKay, MD, Associate Professor of Medicine at the University of California, San Diego, and Co-Leader of the Genitourinary Oncology Disease Team at the Moores Cancer Center, following her presentation on recent trials in this area. They consider such topics as the potential of biomarkers to help some men avoid a surgical resection, the inevitability of therapy resistance in some patients, the potential of ADT alone to cure some patients of prostate cancer, and the comparative value of combination therapies versus monotherapies, among others.
How to cite: McKay, Rana R. “Trials in Neoadjuvant Therapy for Patients with High-Risk Localized Prostate Cancer” October 2020. Accessed Nov 2024. https://dev.grandroundsinurology.com/trials-in-neoadjuvant-therapy-for-patients-with-high-risk-localized-prostate-cancer/
ABOUT THE AUTHOR
Rana R. McKay, MD, is an Associate Professor of Medicine at the University of California, San Diego, and Co-Leader of the Genitourinary Oncology Disease Team at the Moores Cancer Center. She is a board-certified medical oncologist who specializes in treating people with urogenital cancers, including bladder, kidney, prostate, and testicular cancer. Her research interests include the design and implementation of clinical trials to advance the treatment of patients with urologic cancers. She serves as the Principal Investigator of several early phase trials in kidney and prostate cancer. As a clinical investigator, she is committed to advancements that will improve the lives of individuals with cancer. Furthermore, she is interested in understanding mechanisms of response and resistance to specific cancer therapies. Her work has appeared in peer- reviewed publications such as Nature, The Lancet, The Journal of Clinical Oncology, Clinical Cancer Research, Cancer, among others. Dr. McKay earned her medical degree at the University of Florida College of Medicine before completing her residency in Internal Medicine at Johns Hopkins Hospital. She also completed a fellowship in Oncology/Hematology at the Dana-Farber Cancer Institute of Harvard Medical School. She went on to serve as an Assistant Professor at Harvard Medical School and a medical oncologist at Dana-Farber/Brigham and Women’s Cancer Center in Boston before joining UC San Diego Health.
